Edgewise Therapeutics to Showcase Groundbreaking Findings at ESC Congress 2026
Edgewise Therapeutics to Showcase Groundbreaking Findings at ESC Congress 2026
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical organization specializing in cardiovascular diseases, has announced that its CIRRUS-HCM abstract will be presented during a late-breaking science session at the upcoming European Society of Cardiology (ESC) Congress 2026. This significant event will take place from August 28 to August 31 in Munich, Germany. The focus of this presentation will be on the results from the 12-week Phase 2 CIRRUS-HCM trial assessing EDG-7500, a novel treatment for hypertrophic cardiomyopathy (HCM).
Key Details of the Presentation
The presentation, titled CIRRUS-HCM 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy, is set for Monday, August 31, 2026, from 11:30 to 11:45 AM CEST. Dr. Anjali Tiku Owens, an Associate Professor of Medicine specialized in cardiology at the Perelman School of Medicine, will conduct the session. This presentation is part of a larger symposium titled Transforming the Heart: Novel Therapies for Myocardial Disease and Heart Failure, scheduled to be held in Achgabat (Hall A3) at the congress.
About EDG-7500
EDG-7500 is a groundbreaking oral medication designed to selectively modulate cardiac sarcomeres, particularly aiming to enhance cardiac relaxation and minimize early contraction in patients with symptomatic HCM. This approach potentially addresses significant treatment gaps in the management of both obstructive and nonobstructive forms of this condition. The CIRRUS-HCM trial is conducted across more than 20 clinical sites in the United States and consists of multiple phases aimed at elucidating the efficacy and safety of this innovative therapy.
Trial Structure and Phases
- - Part A of the trial focused on evaluating the safety and tolerability of a single oral dose of EDG-7500 in individuals with obstructive HCM (oHCM).
- - Parts B and C included assessments of fixed doses over a 28-day period in both obstructive and nonobstructive HCM, respectively.
- - Part D represents a crucial 12-week study examining dose response and optimization among participants with oHCM and nHCM and is expected to provide critical insights into how this drug can improve patient outcomes.
Understanding Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is recognized as the most prevalent genetic heart disease, impacting about 1 in every 500 individuals. It can severely affect the quality of life and is linked to serious complications such as heart failure and abnormal heart rhythms. Common symptoms experienced by individuals with HCM include breathlessness, fatigue, chest discomfort, irregular heartbeats, and fainting spells. These symptoms arise due to the extreme contraction and thickening of the heart's left ventricular wall, which complicates the heart's ability to relax and fill with blood.
Despite existing treatments for some patients with HCM, there remains a vast unmet medical need for more effective therapeutic options.
About Edgewise Therapeutics
Established with a mission to innovate in treating severe cardiovascular and cardiometabolic diseases, Edgewise Therapeutics has developed a robust pipeline addressing significant health concerns. The company utilizes its proficiencies in muscle physiology and small molecule drug development to advance its therapies, focusing specifically on hypertrophic cardiomyopathy and heart failure. For more updates and insights, visit edgewisetx.com or connect with Edgewise on various social media platforms, including LinkedIn and Twitter.
Conclusion
The upcoming ESC Congress is poised to be a pivotal moment for Edgewise Therapeutics as it demonstrates its commitment to advancing cardiovascular medicine through innovative research and groundbreaking therapeutic options. The anticipation surrounding the late-breaking presentation speaks volumes about the transformative potential of EDG-7500 for HCM patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.